Sarepta Therapeutics (SRPT) PT Lowered to $187 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Sarepta Therapeutics (SRPT) Gains 8.5% Off the Open
August 9, 2018 9:40 AM EDTSarepta Therapeutics (NASDAQ: SRPT) gains 8.5% off the open following results, update.
... MoreBaird Reiterates Outperform on Sarepta Therapeutics (SRPT)
August 9, 2018 9:06 AM EDTBaird reiterated an Outperform rating and $202.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) following a quarterly update. Exondys51 sales come in ahead of expectations at $73.5M vs. consensus estimate of $71.0M, a $8.9 sequential increase over 1Q18. Sales continue to track towards the... More
